#zusduri
Latest news and interesting information about zusduri.
Oppenheimer Reiterates Outperform on UroGen Pharma
Oppenheimer reiterates Outperform on UroGen Pharma with $40 target. Strong commercial momentum for Zusduri driven by physician enthusiasm.
...
